SEC Comment Letter for Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Mar 19, 2012
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: March 19, 2012 · CIK: 0001213037 · Accession: 0000000000-12-013805
AI Filing Summary & Sentiment
File numbers found in text: 000-54556
Letter
March 19, 2012 Via E-mail Dr. Antonius Schuh, Ph.D. Chief Executive Officer TrovaGene, Inc. 11055 Flintkote Avenue, Suite B San Diego, CA 92121
Re: TrovaGene, Inc. Preliminary Proxy Statement on Form PRE 14A Filed March 7, 2012 File No. 000-54556
Dear Dr. Schuh: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely,
/s/ Jeffrey P. Riedler Jeffrey P. Riedler Assistant Director
Show Raw Text
March 19, 2012 Via E-mail Dr. Antonius Schuh, Ph.D. Chief Executive Officer TrovaGene, Inc. 11055 Flintkote Avenue, Suite B San Diego, CA 92121 Re: TrovaGene, Inc. Preliminary Proxy Statement on Form PRE 14A Filed March 7, 2012 File No. 000-54556 Dear Dr. Schuh: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Jeffrey P. Riedler Jeffrey P. Riedler Assistant Director